D56 Thalassemia

Name of the Condition

• Thalassemia

Summary

Thalassemia is a group of inherited blood disorders characterized by reduced hemoglobin production, leading to anemia. Hemoglobin is the protein in red blood cells that carries oxygen. The condition results from mutations in the genes that control hemoglobin synthesis, affecting the balance of alpha and beta globin chains. This imbalance causes red blood cells to be smaller, paler, and less effective at oxygen transport. Thalassemia can range from mild to severe, with symptoms varying based on the specific type and genetic mutations involved.

Causes

Thalassemia is caused by inherited genetic mutations that affect the production of hemoglobin. These mutations are typically passed from parents to children through autosomal recessive inheritance, meaning an individual must inherit two defective genes (one from each parent) to develop the condition. The mutations disrupt the normal production of alpha or beta globin chains, leading to abnormal hemoglobin structure and reduced red blood cell function. The severity of the condition depends on the specific gene mutations and their impact on hemoglobin synthesis.

Risk Factors

• Family history of thalassemia or related blood disorders
• Ethnic background (more common in Mediterranean, Middle Eastern, African, and Southeast Asian populations)
• Consanguineous relationships (parents who are blood relatives)

Symptoms

• Fatigue and weakness due to anemia
• Pale or yellowish skin (jaundice)
• Slow growth or delayed puberty in children
• Enlarged spleen (splenomegaly)
• Bone deformities (e.g., facial bone changes)
• Dark urine (due to hemolysis)
• Shortness of breath

Diagnosis

Diagnosis involves a combination of clinical evaluation, laboratory tests, and genetic analysis. Blood tests assess hemoglobin levels, red blood cell size, and shape. Hemoglobin electrophoresis or high-performance liquid chromatography (HPLC) identifies abnormal hemoglobin types. Genetic testing confirms the specific mutations and determines the thalassemia type. Prenatal testing (e.g., chorionic villus sampling or amniocentesis) may be used to detect the condition in fetuses if there is a family history.

Treatment Options

Treatment depends on the severity of the condition. Mild cases may require no intervention beyond monitoring. Moderate to severe thalassemia often involves regular blood transfusions to manage anemia. Iron chelation therapy is necessary to remove excess iron from repeated transfusions, preventing organ damage. Folic acid supplements support red blood cell production. In some cases, bone marrow or stem cell transplantation may be curative. Gene therapy is an emerging treatment for certain types.

Prognosis and Follow-Up

Prognosis varies by thalassemia type and treatment adherence. With proper management, many individuals with moderate to severe thalassemia can lead active lives. Regular follow-up includes monitoring hemoglobin levels, iron overload, and organ function (e.g., heart, liver). Complications like iron overload or infections require ongoing management. Early diagnosis and consistent care improve long-term outcomes.

Complications

• Iron overload (from transfusions), leading to organ damage (e.g., heart, liver)
• Bone deformities and osteoporosis
• Enlarged spleen (splenomegaly)
• Increased risk of infections
• Gallstones
• Heart problems (e.g., arrhythmias, heart failure)

Lifestyle & Prevention

• Avoid excessive iron supplements unless prescribed
• Maintain a balanced diet rich in folic acid
• Stay up-to-date with vaccinations to reduce infection risk
• Follow medical advice for managing iron levels and organ health
• Genetic counseling for families with a history of thalassemia

When to Seek Professional Help

Seek medical attention if you experience persistent fatigue, jaundice, unexplained bone pain, or signs of anemia. Prompt evaluation is critical for early diagnosis and management, especially in children with growth delays or developmental concerns. Regular check-ups are essential for those with a family history or known risk factors.

Tips for Medical Coders

When coding for thalassemia (ICD10CM code D56), ensure documentation specifies the type (e.g., alpha or beta thalassemia) and severity (e.g., minor, intermedia, major) to support accurate code assignment. Note any complications (e.g., iron overload, splenomegaly) or treatments (e.g., transfusions, chelation) as these may require additional codes. Verify that genetic testing or laboratory results are documented to confirm the diagnosis and guide coding specificity.